➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Moodys
Johnson and Johnson
Express Scripts

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,114,021


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,114,021
Title:Body-associated receiver and method
Abstract: Receivers, which may be external or implantable, are provided. Aspects of receivers of the invention include the presence of one or more of: a high power-low power module; an intermediary module; a power supply module configured to activate and deactivate one or more power supplies to a high power processing block; a serial peripheral interface bus connecting master and slave blocks; and a multi-purpose connector. Receivers of the invention may be configured to receive a conductively transmitted signal. Also provided are systems that include the receivers, as well as methods of using the same. Additionally systems and methods are disclosed for using a receiver for coordinating with dosage delivery systems.
Inventor(s): Robertson; Timothy (Belmont, CA), Omidvar; Fataneh (Danville, CA), Behzadi; Yashar (San Francisco, CA), Arne; Lawrence (Redwood City, CA), Rowberry; Kenneth (San Jose, CA), Hutchison; James (Palo Alto, CA), Leichner; Robert (Menlo Park, CA), Savage; George (Portola Valley, CA), Thompson; Andrew (Portola Valley, CA), Zdeblick; Mark (Portola Valley, CA), Kreidler; Marc (Sunnyvale, CA), Hafezi; Hooman (Redwood City, CA), Duck; Robert (San Francisco, CA)
Assignee: Proteus Biomedical, Inc. (Redwood City, CA)
Application Number:12/673,326
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,114,021

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-004 Nov 13, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-005 Nov 13, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-006 Nov 13, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,114,021

PCT Information
PCT FiledDecember 15, 2009PCT Application Number:PCT/US2009/068128
PCT Publication Date:July 01, 2010PCT Publication Number: WO2010/075115

International Family Members for US Patent 8,114,021

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009330321 ⤷  Free Forever Trial
Australia 2012284125 ⤷  Free Forever Trial
Brazil 112014001397 ⤷  Free Forever Trial
Canada 2747156 ⤷  Free Forever Trial
Canada 2792224 ⤷  Free Forever Trial
Canada 2842952 ⤷  Free Forever Trial
Canada 3030268 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Mallinckrodt
Baxter
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.